Bloomberg reports Alphabet is lining up an $80B equity program — ATM sales, underwritten offerings and a Berkshire‑backed private placement — to pay for massive AI buildout.

A Dallas Fed survey finds two-thirds of Texas companies use AI; a small share say it lowered their need for workers.

Pat Madden’s Phoenix startup Deus X Defense says it merged drones, guards and sensors into one managed offering and counts about 500 staff after two acquisitions.

A new multi‑university preprint finds just 10–15 minutes of AI help can reduce persistence and independent problem‑solving. The finding complicates how schools and workplaces should use chatbots.

A UCLA‑led phase 3 trial found adjuvant selpercatinib dramatically lowers recurrence risk in a rare lung‑cancer subtype. The results could reshape testing and care.

A Baylor‑led consortium's AllFaith Benchmark finds major language models often omit religious perspectives in ethics answers and show conversion biases. The work is open‑sourced for developers and scholars.

The Commerce Department closed a year‑old loophole on Sunday, saying advanced Nvidia and AMD chips sold to companies headquartered in China now require export licenses even when bought through overseas affiliates. The move tightens export checks and could complicate shipments for Bay Area chip and data‑center firms.

Tampa-based XTEND was invited to Phase II of the Pentagon’s Drone Dominance program and will demo its XOS autonomy at Camp Grayling this summer.

Updated CHORD trial numbers presented in Seoul suggest most children with otoferlin‑related deafness gained meaningful hearing after Otarmeni treatment. The therapy was FDA‑cleared in April.

A Houston patient reports no evidence of disease after receiving tile‑based brachytherapy at MD Anderson, while Phase 3 ROADS data presented at ASCO show markedly improved local control.

A St. Paul firm adapted Air Tractor planes with Heatwave floats that scoop 800 gallons in seconds, promising faster, safer wildfire response across Minnesota.

Early trial data show amivantamab shrank—and in some patients erased—tumors in treatment‑resistant head and neck cancer, with results set for ASCO on Sunday. Investigators call the responses striking but preliminary.

A senior Moffitt scientist stepped down after journals and watchdogs flagged image problems in older papers tied to her earlier work. Reviews are ongoing.